Roivant Sciences annual stock-based compensation
2020
2021
2022
2023
2024
2025
Roivant Sciences Stock-Based Compensation Growth & History (ROIV)
Roivant Sciences's stock-based compensation was $346.2M for fiscal 2025.
View full Roivant Sciences company overviewRoivant Sciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2026-03-31 | $346.2M | $57.1M | +19.77% |
| 2024 | 2025-03-31 | $289.0M | $89.4M | +44.78% |
| 2023 | 2024-03-31 | $199.6M | −$18.2M | −8.34% |
| 2022 | 2023-03-31 | $217.8M | −$347.2M | −61.45% |
| 2021 | 2022-03-31 | $565.0M | $480.0M | +564.98% |
| 2020 | 2021-03-31 | $85.0M | — | — |
Roivant Sciences quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-06-30 | $83.3M | $1.2M | +1.42% |
| Q4 2025 | 2026-03-31 | $77.2M | −$6.3M | −7.57% |
| Q3 2025 | 2025-12-31 | $105.0M | $21.3M | +25.47% |
| Q2 2025 | 2025-09-30 | $81.8M | $10.2M | +14.17% |
| Q1 2025 | 2025-06-30 | $82.2M | $32.0M | +63.73% |
| Q4 2024 | 2025-03-31 | $83.5M | $36.8M | +78.68% |
| Q3 2024 | 2024-12-31 | $83.7M | $29.4M | +54.04% |
| Q2 2024 | 2024-09-30 | $71.7M | $22.4M | +45.32% |
| Q1 2024 | 2024-06-30 | $50.2M | $931,000 | +1.89% |
| Q4 2023 | 2024-03-31 | $46.7M | $21.4M | +84.85% |
| Q3 2023 | 2023-12-31 | $54.3M | −$3.4M | −5.90% |
| Q2 2023 | 2023-09-30 | $49.3M | −$12.7M | −20.43% |
| Q1 2023 | 2023-06-30 | $49.3M | −$23.5M | −32.33% |
| Q4 2022 | 2023-03-31 | $25.3M | −$51.9M | −67.24% |
| Q3 2022 | 2022-12-31 | $57.7M | −$13.5M | −18.94% |
| Q2 2022 | 2022-09-30 | $62.0M | −$335.3M | −84.40% |
| Q1 2022 | 2022-06-30 | $72.8M | $53.5M | +277.78% |
| Q4 2021 | 2022-03-31 | $77.2M | $37.7M | +95.63% |
| Q3 2021 | 2021-12-31 | $71.2M | $53.9M | +311.08% |
| Q2 2021 | 2021-09-30 | $397.3M | $383.4M | +2755.48% |
| Q1 2021 | 2021-06-30 | $19.3M | $5.0M | +34.96% |
| Q4 2020 | 2021-03-31 | $39.4M | — | — |
| Q3 2020 | 2020-12-31 | $17.3M | — | — |
| Q2 2020 | 2020-09-30 | $13.9M | — | — |
| Q1 2020 | 2020-06-30 | $14.3M | — | — |
Roivant Sciences stock-based compensation trends
Over the last five fiscal years, Roivant Sciences's stock-based compensation increased from $85.0M to $346.2M, a change of $261.2M. The latest reported quarter, Q1 2026, shows $83.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Roivant Sciences source filings ↗